Comparison of minimal residual disease as outcome predictor for AML patients in first complete remission undergoing myeloablative or nonmyeloablative allogeneic hematopoietic cell transplantation
about
Reduced-intensity conditioning allogeneic hematopoietic-cell transplantation for older patients with acute myeloid leukemiaRisk factors for relapse after allogeneic transplantation in acute myeloid leukemiaMinimal Residual Disease in Acute Myeloid Leukemia of Adults: Determination, Prognostic Impact and Clinical ApplicationsDNMT3A mutations promote anthracycline resistance in acute myeloid leukemia via impaired nucleosome remodelingMinimal residual disease prior to allogeneic hematopoietic cell transplantation in acute myeloid leukemia: a meta-analysisMinimal Residual Disease in Acute Myeloid Leukemia: Still a Work in Progress?Haploidentical allograft is superior to matched sibling donor allograft in eradicating pre-transplantation minimal residual disease of AML patients as determined by multiparameter flow cytometry: a retrospective and prospective analysis.The Future of Targeting FLT3 Activation in AML.Number of courses of induction therapy independently predicts outcome after allogeneic transplantation for acute myeloid leukemia in first morphological remission.A multigene array for measurable residual disease detection in AML patients undergoing SCTMyeloablative, but not Reduced-Intensity, Conditioning Overcomes the Negative Effect of Flow-Cytometric Evidence of Leukemia in Acute Myeloid LeukemiaAllogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia: Time to Move Toward a Minimal Residual Disease-Based Definition of Complete Remission?Hematologic Recovery after Pretransplant Chemotherapy Does Not Influence Survival after Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia Patients.Pre- and post-transplant quantification of measurable ('minimal') residual disease via multiparameter flow cytometry in adult acute myeloid leukemia.Minimal Identifiable Disease and the Role of Conditioning Intensity in Hematopoietic Cell Transplantation for Myelodysplastic Syndrome and Acute Myelogenous Leukemia Evolving from Myelodysplastic SyndromeI walk the other line: myelodysplastic/myeloproliferative neoplasm overlap syndromes.Acute myeloid leukemia--major progress over four decades and glimpses into the future.Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response.Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes.Relapse of AML after hematopoietic stem cell transplantation: methods of monitoring and preventive strategies. A review from the ALWP of the EBMT.Acute Myeloid Leukemia: How Do We Measure Success?Minimal Residual Disease in Acute Myeloid Leukemia.Bone marrow evaluation for diagnosis and monitoring of acute myeloid leukemia.Predicting Chemotherapy Resistance in AML.Pre-transplantation minimal residual disease with cytogenetic and molecular diagnostic features improves risk stratification in acute myeloid leukemia.Minimal Residual Disease Monitoring of Acute Myeloid Leukemia by Massively Multiplex Digital PCR in Patients with NPM1 Mutations.The clinical significance of negative flow cytometry immunophenotypic results in a morphologically scored positive bone marrow in patients following treatment for acute myeloid leukemiaMultigene Measurable Residual Disease Assessment Improves Acute Myeloid Leukemia Relapse Risk Stratification in Autologous Hematopoietic Cell TransplantationIncreasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States.Minimal/measurable residual disease in AML: consensus document from ELN MRD Working Party.Methods of Detection of Measurable Residual Disease in AML.History of consolidation is prognostic in acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplantation in minimal residual disease-negative first complete remission.Minimal residual disease by either flow cytometry or cytogenetics prior to an allogeneic hematopoietic stem cell transplant is associated with poor outcome in acute myeloid leukemia.FLT3 as a marker of minimal residual disease: Time to re-think?Comparison of Multiparameter Flow Cytometry Immunophenotypic Analysis and Quantitative RT-PCR for the Detection of Minimal Residual Disease of Core Binding Factor Acute Myeloid Leukemia.Disease burden and conditioning regimens in ASCT1221, a randomized phase II trial in children with juvenile myelomonocytic leukemia: A Children's Oncology Group study.The impact of minimal residual disease prior to unmanipulated haploidentical hematopoietic stem cell transplantation in patients with acute myeloid leukemia in complete remission.Allogeneic transplant for FLT3-ITD+ AML: room for improvement.Hematopoietic cell transplant for acute myeloid leukemia and myelodysplastic syndrome: conditioning regimen intensity
P2860
Q26744283-A20A55F5-1B78-41C5-8EBE-B5C8FB7D6B2CQ26771438-A5C5F919-9C97-4D0F-96F0-3230745B9491Q28073464-3ED0E853-D0FB-40AE-BA03-94CC55B9EF1AQ30355347-C45CA430-1648-44A0-93F1-AC4BB3E2FFD3Q33815986-396310CB-8ECA-4029-BCA4-3131BA6911E1Q33832709-D00FB98F-90A5-4D16-9B90-883E98B5DC97Q33868700-E666FA68-04D7-4B84-8D06-E05F7484719AQ34555386-F3875C06-182F-4607-9C8D-7778A69A388EQ34979564-B2707FAA-0BB2-49FF-A790-F7CED3116C8AQ35582360-7B797316-85F0-4A0F-AFA5-D1E3B4FA1F19Q36723108-AAFA8745-F054-48F9-8554-6C2D5F02FC1CQ36914475-42D4FE10-8C85-45A8-AA6E-AB6C7C8FC3A3Q36961604-F6F157F5-B762-4616-ACB8-A0E687A56F96Q37072126-D4A54594-2738-4465-99D8-934B0DE3C186Q37207443-195B4A65-507B-4D17-AAA2-BEFF62FBA8E1Q38246598-AB944A9C-E881-47DA-95FC-19143CC281CFQ38644941-700619A8-B9FF-4872-B8B1-183FD971D0FBQ38674045-029E42E2-574D-4B3C-B11C-9A66EF90DF70Q38852431-C3C05BB7-1915-428A-B626-2C01F495CB2CQ38863489-CD81C235-4835-4E52-B677-DBA8F53D7838Q38948650-D83237E2-F44C-4BB4-910F-A2961311E56BQ39097771-0AFE3DBE-5A3D-4CBA-A716-009C0D8CFC4DQ39132424-A7CCF246-FA4F-4143-AA45-CE93DBF15267Q39233284-8BEA1BD5-FEE3-4DE7-8F92-816FBA6285D3Q39474999-28D5F53F-8FD7-4348-B716-F4AF29217C9BQ40471975-EDFCA5AF-53C7-4ECC-BCE5-8424645C9F3CQ41264435-F4454DB2-3863-4304-B1B4-131DAD43B041Q42711146-CFAB0827-9261-4F76-A937-FF56C679E875Q46389618-8F750B4D-5D25-43FA-949E-D9165AF190A5Q47734674-EE2516CF-6FEE-4893-BB06-694DCBD9F0B6Q47862030-090C47AF-B1AB-44D1-B9EA-727457A63742Q48227196-DA12B0C7-3E0F-4747-905A-C5C61FD6145FQ48236706-73569D2D-B6C5-4C0F-8096-B482095E96ABQ50921275-20CF4D31-EFCB-43AE-ADDE-B0915EFB5FBDQ51704129-5C4CF31C-1D9D-4B70-9DC5-CB3DABAED4D9Q52661221-C683EF02-B376-4685-BD0C-EED3E929C82EQ53011046-255589B6-874C-4511-8974-00D5E660117DQ54208508-44791809-E2FB-4665-B8E4-580B2707947BQ58719438-B6241124-87D5-464B-B792-7B8906F6F829
P2860
Comparison of minimal residual disease as outcome predictor for AML patients in first complete remission undergoing myeloablative or nonmyeloablative allogeneic hematopoietic cell transplantation
description
2014 nî lūn-bûn
@nan
2014 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Comparison of minimal residual ...... topoietic cell transplantation
@ast
Comparison of minimal residual ...... topoietic cell transplantation
@en
Comparison of minimal residual ...... topoietic cell transplantation
@nl
type
label
Comparison of minimal residual ...... topoietic cell transplantation
@ast
Comparison of minimal residual ...... topoietic cell transplantation
@en
Comparison of minimal residual ...... topoietic cell transplantation
@nl
prefLabel
Comparison of minimal residual ...... topoietic cell transplantation
@ast
Comparison of minimal residual ...... topoietic cell transplantation
@en
Comparison of minimal residual ...... topoietic cell transplantation
@nl
P2093
P2860
P356
P1433
P1476
Comparison of minimal residual ...... topoietic cell transplantation
@en
P2093
B E Storer
B Gyurkocza
B M Sandmaier
C D Godwin
M L Sorror
R B Walter
S A Buckley
P2860
P2888
P304
P356
10.1038/LEU.2014.173
P577
2014-06-03T00:00:00Z
P5875
P6179
1000304383